Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
Erasca stock moves on ERAS-0015 licensing and clinical data anticipation Erasca (ERAS) has been in focus after securing exclusive global rights to its pan RAS candidate ERAS-0015, and as investors watch for initial clinical data in RAS mutant solid tumors. See our latest analysis for Erasca. The latest ERAS-0015 licensing move and anticipation around clinical data come after a sharp re-rating in the shares, with a 90-day share price return above 300% and a 1-year total shareholder return that is very large. This suggests momentum has been building as investors reassess both growth prospects and risk. If you are looking beyond a single oncology name, this could be a good moment to broaden your watchlist with other health-focused AI opportunities using the 36 healthcare AI stocks After a 90 day return above 300%, a very large 1 year total return, and a recent close at US$14.60, the key question is whether Erasca still offers upside or if the market is already pricing in futur
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) Adds 13%; Soars 310% YTD [Yahoo! Finance]Yahoo! Finance
- Erasca (ERAS) had its price target raised by JPMorgan Chase & Co. from $24.00 to $25.00. They now have an "overweight" rating on the stock.MarketBeat
- Erasca (ERAS) had its price target raised by Guggenheim from $12.00 to $20.00. They now have a "buy" rating on the stock.MarketBeat
- Erasca (ERAS) had its price target raised by Piper Sandler from $11.00 to $18.00. They now have an "overweight" rating on the stock.MarketBeat
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/16/26 - Form 144
- 3/12/26 - Form 10-K
- 3/12/26 - Form 8-K
- ERAS's page on the SEC website